Tal Zaks, Moderna CMO (Moderna via YouTube)

NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

The NI­AID and Mod­er­na have spelled out pos­i­tive Phase I safe­ty and ef­fi­ca­cy da­ta for their Covid-19 vac­cine mR­NA-1273 — high­light­ing the first full, clear sketch of ev­i­dence that back-to-back jabs at the dose se­lect­ed for Phase III rou­tine­ly pro­duced a swarm of an­ti­bod­ies to the virus that ex­ceed­ed lev­els seen in con­va­les­cent pa­tients — typ­i­cal­ly in mul­ti­ples in­di­cat­ing a pro­tec­tive re­sponse.

Mod­er­na ex­ecs say plain­ly that this first stage of re­search pro­duced ex­act­ly the kind of ef­fi­ca­cy they hoped to see in hu­mans, with a man­age­able safe­ty pro­file.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.